Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
M7437 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Part 1: Dose-escalation Cohort | EXPERIMENTAL | - |
| Part 2: Dose-Expansion Cohort | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| M7437 | DRUG | Participants will receive M7437 as an intravenous infusion at a dose corresponding to their assigned cohort. Dose escalation will occur between cohorts, with 3-4 participants enrolled at each dose level before proceeding to the next higher dose. |
Inclusion Criteria: * Participants have histologically proven advanced solid tumors with known prevalent and high Ly6E expression, Disease characteristic: Participants should have an unresectable locally advanced or metastatic solid tumor that is refractory to standard therapies, or have no standar...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 3 | PHASE2 | Pembrolizumab, Gardasil 9 |
| Incyte Corporation | INCY | 1 | PHASE2 | Retifanlimab |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115 |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | Aldesleukin |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
M7437 is an investigational small molecule being developed by Merck KGaA for the treatment of advanced solid tumors. It is in Phase 1 clinical development and is being studied in a biomarker-selected patient population. M7437 has not been approved for any indication and remains an experimental therapy in early-stage testing.
M7437 is being evaluated for the treatment of advanced solid tumors in adults. The Phase 1 study enrolls patients 18 years and older with advanced solid tumors across the United States, Canada, Japan, and Spain. It is investigational and has not been approved for treating solid tumors or any other condition.
M7437 is being developed by Merck KGaA, which trades over the counter in the United States under the ticker MKGAF. The company is running the Phase 1 program for the drug in advanced solid tumors. Merck KGaA is the sole sponsor identified for the M7437 clinical program.
M7437 is in Phase 1 clinical development. It is an investigational agent and has not received FDA approval. The single registered trial is currently recruiting participants, and no trials for M7437 have been completed. The program remains in early-stage clinical testing for advanced solid tumors.
M7437 is being studied in one clinical trial, NCT07360314, titled Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors. The Phase 1 study is recruiting and plans to enroll 138 participants with advanced solid tumors. It is a controlled, non-randomized, open-label trial without double blinding, conducted in the United States, Canada, Japan, and Spain.